Austco Healthcare Limited (AU:AHC)
ASX:AHC
Want to see AU:AHC full AI Analyst Report?
Top Page
Austco Healthcare Limited
(Sydney:AHC)
Select Model
Select Model
Rating:65Neutral
Price Target:
AU$0.23
▼(-32.06% Downside)
Action:Reiterated
Date:06/18/26
The score is driven by solid financial fundamentals (strong growth and low leverage) and a reasonable valuation (low P/E). These positives are partially offset by weak technicals, with the stock trading below major moving averages and negative momentum indicators.
Positive Factors
Revenue Growth
Sustained revenue growth shows durable demand for clinical communications and workflow products across hospitals and aged care. Over 2–6 months this supports predictable backlog, scale benefits and recurring service revenues that underpin stable top-line expansion and investment capacity.
Negative Factors
Net Margin Compression
A material fall in net margin signals rising operating costs, pricing pressure or higher overheads that can erode earnings durability. If persistent, this reduces free cash available for reinvestment and weakens the company’s ability to fund growth or return capital absent revenue improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth shows durable demand for clinical communications and workflow products across hospitals and aged care. Over 2–6 months this supports predictable backlog, scale benefits and recurring service revenues that underpin stable top-line expansion and investment capacity.
Read all positive factors
Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$82.45M
Dividend YieldN/A
Average Volume (3M)242.22K
Price to Earnings (P/E)10.7
Beta (1Y)0.80
Revenue Growth28.40%
EPS Growth-22.71%
CountryAU
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding374,751,280
10 Day Avg. Volume336,746
30 Day Avg. Volume242,221
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)2.08
Price to Sales (P/S)1.32
P/FCF Ratio10.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.45Price Target Upside32.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$106.10M
Austco Healthcare Limited Business Overview & Revenue Model
Company Description
Austco Healthcare Limited, through its subsidiaries, operates as a global entity focused on the development, production, and comprehensive servicing of advanced healthcare and electronic communication systems. The company's market reach extends ac...
How the Company Makes Money
null...
Austco Healthcare Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.73M | 81.41M | 58.15M | 41.98M | 35.88M | 31.25M |
| Gross Profit | 34.91M | 42.37M | 30.67M | 6.68M | 18.85M | 16.71M |
| EBITDA | 16.23M | 11.10M | 8.11M | 3.60M | 3.73M | 5.01M |
| Net Income | 7.75M | 5.93M | 7.08M | 2.26M | 2.33M | 3.42M |
Balance Sheet | ||||||
| Total Assets | 87.50M | 91.07M | 68.70M | 37.85M | 34.03M | 27.18M |
| Cash, Cash Equivalents and Short-Term Investments | 15.23M | 14.48M | 13.56M | 4.67M | 7.63M | 7.77M |
| Total Debt | 7.68M | 3.88M | 1.78M | 524.00K | 979.00K | 1.15M |
| Total Liabilities | 28.76M | 39.34M | 24.33M | 12.85M | 10.94M | 7.88M |
| Stockholders Equity | 58.76M | 51.73M | 44.38M | 25.00M | 23.09M | 19.30M |
Cash Flow | ||||||
| Free Cash Flow | 17.39M | 10.66M | 7.45M | -1.25M | 315.00K | 1.91M |
| Operating Cash Flow | 20.36M | 13.42M | 11.35M | 320.00K | 1.94M | 3.21M |
| Investing Cash Flow | -14.00M | -12.32M | -11.06M | -1.57M | -1.63M | -1.30M |
| Financing Cash Flow | -1.08M | -402.00K | 8.84M | -1.58M | -312.00K | -474.00K |
Austco Healthcare Limited Technical Analysis
Negative
0.34
Price Trends
0.30
Negative
0.33
Negative
0.36
Negative
Market Momentum
-0.03
Negative
35.18
Neutral
78.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHC, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.30, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 35.18 is Neutral, neither overbought nor oversold. The STOCH value of 78.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHC.
Austco Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$82.45M | 10.74 | 14.03% | ― | 28.40% | -22.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$38.22M | -27.64 | -1.32% | ― | 6.20% | 95.19% | |
45 Neutral | AU$2.30B | -12.39 | -890.76% | ― | -0.80% | -249.48% | |
44 Neutral | AU$87.03M | -10.86 | -40.65% | ― | -100.00% | -11.11% | |
43 Neutral | AU$61.76M | -8.12 | -59.96% | ― | ― | ― | |
42 Neutral | AU$70.60M | -3.58 | -54.48% | ― | 17.24% | -20.00% |
* Healthcare Sector Average
AU:AHC
Austco Healthcare Limited
0.23
-0.06
-20.69%
AU:CYC
Cyclopharm Limited
0.57
-0.40
-41.15%
AU:SHG
Singular Health Group Ltd
0.20
-0.16
-45.21%
AU:TRJ
Trajan Group Holdings Ltd
0.27
-0.47
-63.95%
AU:4DX
4DMedical Ltd
4.54
4.28
1646.15%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.03
-26.04%
Austco Healthcare Limited Corporate Events
Austco lifts FY26 profit outlook on strong sales and major U.S. rollout
May 31, 2026
Austco Healthcare, a specialist in clinical communication and workflow systems for hospitals and aged care, is expanding its footprint across markets including Australia, New Zealand, Canada and the United States. Its portfolio, anchored by the Ta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.